Vir Biotechnology Inc. Common Stock (VIR)
Stock · NASDAQ · Health Care
$9.97as of 10/16/2026
Price chart
Active signals
VIR Signal Track Record
How signals performed across all stocks →What VIR's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 35 | -1.0% | 49% | September 18, 2026 |
| Bollinger Band BreakdownActive now | 27 | -0.4% | 48% | July 24, 2026 |
| Bollinger Band Breakout | 24 | -1.8% | 46% | October 5, 2026 |
| 200-Day Moving Average TouchActive now | 10 | -4.3% | 40% | November 1, 2024 |
| Any 20-session window (baseline) | -0.3% | 49% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About VIR
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A a…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 367
- Website
- www.vir.bio/
Fundamentals
- 1-day range
- $9.91$10.45
- Market cap
- $1.48B
- P/E (trailing)
- —
- P/E (forward)
- -4.00
- EPS (trailing)
- $-1.01
- Dividend yield
- —
- Beta
- 1.77
- Avg. volume
- 1.94M
How Vir Biotechnology Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 23, 2026 · via SEC EDGAR / Finnhub
Forecasts
9 analyst ratings
Vir Biotechnology Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- VIRVir Biotechnology Inc. Common Stock$9.96▼ 4.87%Market cap $1.48BP/E —$4.82$12
- SLBTSL Science Holding Limited Ordinary Shares$1.53▼ 1.29%Market cap $1.53BP/E —$1.42$14.5
- MAZEMaze Therapeutics Inc. Common Stock$27.53▲ 0.18%Market cap $1.58BP/E —$21.95$53.65
- GLUEMonte Rosa Therapeutics Inc. Common Stock$9.74▼ 3.75%Market cap $1.33BP/E —$8.94$25.77
- IMCRImmunocore Holdings plc American Depositary Shares$29.4▼ 0.27%Market cap $1.66BP/E —$27.5$40.71
- VORVor Biopharma Inc. Common Stock$18.03▼ 6.77%Market cap $1.28BP/E 1.82$6.5$33.42
- NVAXNovavax Inc. Common Stock$11.26▼ 12.17%Market cap $1.27BP/E —$6.2$13.39
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| VIR Vir Biotechnology Inc. Common Stock | $1.48B | — | $9.96 | ▼ 4.87% | $4.82$12 |
| SLBT SL Science Holding Limited Ordinary Shares | $1.53B | — | $1.53 | ▼ 1.29% | $1.42$14.5 |
| MAZE Maze Therapeutics Inc. Common Stock | $1.58B | — | $27.53 | ▲ 0.18% | $21.95$53.65 |
| GLUE Monte Rosa Therapeutics Inc. Common Stock | $1.33B | — | $9.74 | ▼ 3.75% | $8.94$25.77 |
| IMCR Immunocore Holdings plc American Depositary Shares | $1.66B | — | $29.4 | ▼ 0.27% | $27.5$40.71 |
| VOR Vor Biopharma Inc. Common Stock | $1.28B | 1.82 | $18.03 | ▼ 6.77% | $6.5$33.42 |
| NVAX Novavax Inc. Common Stock | $1.27B | — | $11.26 | ▼ 12.17% | $6.2$13.39 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Vir Biotechnology, Gilead Strike Deal for Novel Tumor Treatmentsbenzinga · 10/14/2026
- Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate CancerYahoo · 10/8/2026
- Vir Biotechnology Receives FDA Fast Track Designation For VIR-5500 To Treat Metastatic Castration-Resistant Prostate CancerBenzinga · 10/8/2026
- How Upcoming SOLSTICE Phase 2 HDV Data Could Shape Vir Biotechnology’s (VIR) Investment NarrativeYahoo · 10/8/2026
- Vir Biotechnology Appoints David Liu as Chief Medical OfficerYahoo · 10/7/2026
- HC Wainwright & Co. Maintains Buy on Vir Biotechnology, Raises Price Target to $22Benzinga · 10/7/2026
- Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD’s The Liver Meeting® 2026Yahoo · 10/5/2026
- Vir Biotechnology To Reveal Expanded Phase 2 SOLSTICE Results for Elebsiran And Tobevibart In Hepatitis Delta at AASLD’s The Liver Meeting 2026Benzinga · 10/5/2026
- Vir Biotechnology Appoints Aziz Sawaf as Chief Financial OfficerYahoo · 10/1/2026
Insider Activity
Insider Actions →- Robert J. More · August 11, 2026 · J8.0K
- Timothy Coughlin · June 9, 2026 · Grant16.0K
- Timothy Coughlin · June 9, 2026 · Grant8.0K
- Janet Napolitano · June 1, 2026 · Sale3.2K @ $9.45
- Brent Sabatini · June 1, 2026 · Sale379 @ $9.45
- Robert J. More · May 27, 2026 · Grant16.0K
- Robert J. More · May 27, 2026 · Grant8.0K
- Norbert W. Bischofberger · May 27, 2026 · Grant16.0K
- Norbert W. Bischofberger · May 27, 2026 · Grant8.0K
- Janet Napolitano · May 27, 2026 · Grant16.0K
- Janet Napolitano · May 27, 2026 · Grant8.0K
- Ramy Farid · May 27, 2026 · Grant16.0K
- Ramy Farid · May 27, 2026 · Grant8.0K
- Charles Elliott Sigal · May 27, 2026 · Grant16.0K
- Charles Elliott Sigal · May 27, 2026 · Grant8.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 128.70M
- Total value held
- $1.14B
- Institutional holders
- 247
- Unknown18.00M
- Unknown12.92M
- Unknown10.95M
- Unknown8.55M
- Unknown7.14M
- Unknown5.38M
- Unknown3.25M
- Unknown2.85M
- Unknown2.74M
- Unknown2.66M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Vir Biotechnology Secures $1.875B Gilead Deal for Cancer Drug Candidates
Vir Biotechnology entered a $1.875 billion partnership with Gilead that includes an upfront cash payment and shares, plus up to $1.785 billion in milestone payments and royalties. The collaboration also covers three PRO‑XTEN dual‑masked T‑cell engager candidates for solid tumors, with one, VIR‑5500, receiving FDA Fast‑Track status for metastatic castration‑resistant prostate cancer. These developments expand Vir’s oncology pipeline and strengthen its relationship with a major biopharma partner.
Vir Biotechnology Secures $1.875B Gilead Deal for Cancer Drug Candidates. Vir Biotechnology entered a $1.875 billion partnership with Gilead that includes an upfront cash payment and shares, plus up to $1.785 billion in milestone payments and royalties. The collaboration also covers three PRO‑XTEN dual‑masked T‑cell engager candidates for solid tumors, with one, VIR‑5500, receiving FDA Fast‑Track status for metastatic castration‑resistant prostate cancer. These developments expand Vir’s oncology pipeline and strengthen its relationship with a major biopharma partner.